POL regulation of drugs and vaccines
(Unterschied zwischen Versionen)
| Zeile 4: | Zeile 4: | ||
{{tp|p=32509289|t=2020. The case for compulsory licensing during COVID-19.|pdf=|usr=008}} | {{tp|p=32509289|t=2020. The case for compulsory licensing during COVID-19.|pdf=|usr=008}} | ||
{{tp|p=32556334|t=2020. Regulating drugs, medical devices, and diagnostic tests in the European Union: early lessons from the COVID-19 pandemic?|pdf=|usr=011}} | {{tp|p=32556334|t=2020. Regulating drugs, medical devices, and diagnostic tests in the European Union: early lessons from the COVID-19 pandemic?|pdf=|usr=011}} | ||
| + | {{tp|p=32577858|t=2020. Pricing vaccines and drugs in Europe: worth differentiating?|pdf=|usr=015}} | ||
| + | {{tp|p=32617864|t=2020. Short and long term impacts of COVID-19 on the pharmaceutical sector.|pdf=|usr=012}} | ||
Version vom 6. Dezember 2020, 13:53 Uhr
32092455 2020. New regulatory strategies to manage medicines shortages in Europe.
32282038 2020. The VACCINES Act, Deciphering Vaccine Hesitancy in the Time of COVID19.
32406905 2020. Navigating regulatory statutes during the Coronavirus Disease 2019.
32509289 2020. The case for compulsory licensing during COVID-19.
32556334 2020. Regulating drugs, medical devices, and diagnostic tests in the European Union: early lessons from the COVID-19 pandemic?
32577858 2020. Pricing vaccines and drugs in Europe: worth differentiating?
32617864 2020. Short and long term impacts of COVID-19 on the pharmaceutical sector.
